These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1498856)

  • 1. CSF noradrenergic activity and sleep EEG in clinically stable schizophrenic patients after haloperidol withdrawal.
    van Kammen DP; Yao J; Gurklis J; O'Connor D; Nofzinger E; Peters JL
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():325A-326A. PubMed ID: 1498856
    [No Abstract]   [Full Text] [Related]  

  • 2. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients.
    Neylan TC; van Kammen DP; Kelley ME; Peters JL
    Arch Gen Psychiatry; 1992 Aug; 49(8):643-9. PubMed ID: 1637254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.
    Forman SD; Bissette G; Yao J; Nemeroff CB; van Kammen DP
    Schizophr Res; 1994 Apr; 12(1):43-51. PubMed ID: 8018584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
    Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M
    Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Norepinephrine turnover under neuroleptic treatment of schizophrenic syndromes (author's transl)].
    Eben E; Ackenheil M; Rüther E
    Arzneimittelforschung; 1978; 28(9):1498. PubMed ID: 38809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol and norepinephrine levels in alcohol withdrawal. Correlations with clinical signs.
    Hawley RJ; Major LF; Schulman EA; Linnoila M
    Arch Gen Psychiatry; 1985 Nov; 42(11):1056-62. PubMed ID: 4051683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free.
    Nofzinger EA; van Kammen DP; Gilbertson MW; Gurklis JA; Peters JL
    Biol Psychiatry; 1993 Jun 1-15; 33(11-12):829-35. PubMed ID: 8104041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
    van Kammen DP; Peters J; Yao J; van Kammen WB; Neylan T; Shaw D; Linnoila M
    Arch Gen Psychiatry; 1990 Feb; 47(2):161-8. PubMed ID: 1689140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
    van Kammen DP; Guidotti A; Kelley ME; Gurklis J; Guarneri P; Gilbertson MW; Yao JK; Peters J; Costa E
    Biol Psychiatry; 1993 Oct; 34(8):515-22. PubMed ID: 8274578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid studies of monoamine metabolism in schizophrenia.
    van Kammen DP; Peters J; van Kammen WB
    Psychiatr Clin North Am; 1986 Mar; 9(1):81-97. PubMed ID: 2421272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Peters JL
    Arch Gen Psychiatry; 1995 Aug; 52(8):673-8. PubMed ID: 7543265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships.
    van Kammen DP; Peters J; Yao J; Neylan T; Beuger M; Pontius E; O'Connor DT
    Schizophr Res; 1991 Dec; 6(1):31-9. PubMed ID: 1723893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired noradrenergic transmission in schizophrenia?
    van Kammen DP; Antelman S
    Life Sci; 1984 Apr; 34(15):1403-13. PubMed ID: 6323903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHPG excretion and EEG sleep in primary depression.
    Kupfer DJ; Holzer BC; Edwards DJ; Coble PA; Spiker DG; Neil JF
    Psychiatry Res; 1980 Oct; 3(2):133-40. PubMed ID: 6947306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
    Thaker GK; Wagman AM; Kirkpatrick B; Tamminga CA
    Biol Psychiatry; 1989 Jan; 25(1):75-86. PubMed ID: 2563233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between CSF noradrenaline levels, C-EEG indicators of activation and psychosis ratings in drug-free schizophrenic patients.
    Kemali D; Maj M; Iorio G; Marciano F; Nolfe G; Galderisi S; Salvati A
    Acta Psychiatr Scand; 1985 Jan; 71(1):19-24. PubMed ID: 3969838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine beta-hydroxylase deficiency.
    O'Connor DT; Cervenka JH; Stone RA; Levine GL; Parmer RJ; Franco-Bourland RE; Madrazo I; Langlais PJ; Robertson D; Biaggioni I
    Clin Sci (Lond); 1994 Feb; 86(2):149-58. PubMed ID: 8143425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF chromogranin A-like immunoreactivity in schizophrenia: relationships with REM latency and slow wave sleep.
    van Kammen DP; O'Connor DT; Neylan TC; Mouton A; Gurklis JA; Gilbertson MW; Peters JL
    Psychiatry Res; 1992 Apr; 42(1):53-63. PubMed ID: 1603881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.